Evidence map›Paper›PMID 40718489›Full record

ArticleFrontiers in immunology2025

Intranasal monoclonal antibodies to mugwort pollen reduce allergic inflammation in a mouse model of allergic rhinitis and asthma.

Kairat Tabynov, Igor Nedushenko, Elmira Tailakova, Akbota Sergazina, Turlan Bolatbekov, Gleb Fomin, Tair Nurpeissov, Utsav Vaghasiya, Nikolai Petrovsky, Anton Demyanov and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kairat TabynovInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Igor NedushenkoInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Elmira TailakovaInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Akbota SergazinaInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Turlan BolatbekovInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Gleb FominPreclinical Research Laboratory with Vivarium, M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan.
Tair NurpeissovDepartment of General Immunology, Asfendiyarov Kazakh National Medical University (KazNMU), Almaty, Kazakhstan.
Utsav VaghasiyaVaxine Pty Ltd, Adelaide, SA, Australia.
Nikolai PetrovskyVaxine Pty Ltd, Adelaide, SA, Australia.
Anton DemyanovXema Oy, Lappeenranta, Finland.
Yuri LebedinXema Oy, Lappeenranta, Finland.
Kaissar TabynovInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Allergen-specific monoclonal antibodies (mAbs) have recently emerged as promising tools in allergy therapy, particularly for patients who do not respond adequately to allergen-specific immunotherapy (AIT). While previous studies have explored systemic delivery routes, the efficacy of local intranasal administration of allergen-specific mAb remains largely unexplored. Methods: Hybridoma-derived murine IgG Results: Five IgG Conclusion: Intranasal delivery of allergen-specific mAbs represents a novel, non-invasive strategy to prevent both upper and lower airway allergic inflammation. Our findings establish proof-of-concept for this approach and warrant further development.

Indexed as

Antibodies, MonoclonalArtemisiaAsthmaPollenRhinitis, AllergicRhinitis, Allergic, SeasonalAdministration, IntranasalAllergensAnimalsAntigens, PlantCytokinesDisease Models, AnimalFemaleHumansImmunoglobulin EImmunoglobulin GAllergensAntibodies, MonoclonalAntigens, PlantCytokinesImmunoglobulin EImmunoglobulin Gairway inflammationallergen-specific monoclonal antibodyallergic rhinitisArtemisia vulgarisasthmaIgE-blocking antibodyintranasal immunotherapyTh2 cytokines

Identifiers

PMID40718489
PMCPMC12289598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.